TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02261480

Intervention type: OTHER
Intervention: Nasopharyngeal wash
Description: Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.

Intervention type: OTHER
Intervention: Nasopharyngeal wash
Description: Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
Study: NCT03943667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
Study: NCT00381316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium Tc99m Tetrofosmin injections
Description: Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thallous Chloride T1-201
Description: Myoview SPECT Imaging
Study: NCT02044146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor, Prasugrel, Clopidogrel
Study: NCT00936039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: unloading
Description: 2 weeks of unloading of a single leg
Study: NCT03837535

Intervention type: PROCEDURE
Intervention: Surgery
Description: Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
Study: NCT00920270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized colistin
Description: nebulized colistin 75 mg every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotics
Description: conventional parenteral antibiotics
Study: NCT03704922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Red cell units for transfusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Red cell units for transfusion
Study: NCT02597361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo o.d. to match 150mg or 300mg irbesartan tablets
Study: NCT00693108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Study: NCT04629157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innova Lateral Flow Device
Description: The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
Study: NCT02526316

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: P16_37-63 peptide combined with Montanide® ISA-51 VG
Description: Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: P16_37-63 peptide without Montanide® ISA-51 VG
Description: Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
Study: NCT02533128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liberal blood pressure management
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tight blood pressure management
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
Study: NCT03640988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dermaPACE
Description: Shockwave application
Study: NCT03302936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Description: to be given preoperatively
Study: NCT03548090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 4-week exercise intervention
Description: This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 4-week exercise intervention
Description: This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
Study: NCT01900275

Intervention type: OTHER
Intervention: Urine collection
Description: Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
Study: NCT01726777

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Normal cheddar cheese
Study: NCT01726777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3 supplemented cheddar cheese
Study: NCT01319760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella 2.5 support
Description: Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care (Control)
Description: Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
Study: NCT01612793

Intervention type: DEVICE
Intervention: AlphaCore Device
Description: multiple stimulation treatments per day for duration of hospitalization
Study: NCT03822403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EQUIA
Description: Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gradia Direct Posterior
Description: The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
Study: NCT00909285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS stimulation
Description: TMS stimulation and cognitive training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham comparator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: TMS stimulation and cognitive training
Study: NCT00883194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF-108
Description: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRF-108 Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF-110
Study: NCT04160403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy intervention
Description: NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
Study: NCT01378390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded autologous adipose-derived adult stem cells (eASCs)
Description: Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
Study: NCT04795804

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk Oligossaccharide
Description: The day before the CIDs, the participants receive the supplements 3x a day in randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The day before the CIDs, the participants receive the supplements 3x a day in randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human Milk Oligossaccharide and resistant starch
Description: The day before the CIDs, the participants receive the supplements 3x a day in randomized order
Study: NCT00296348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids
Description: oral
Study: NCT03704051

Intervention type: BEHAVIORAL
Intervention: Mode of Feeding (breastfeeding versus bottle-feeding)
Description: Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.

Intervention type: BEHAVIORAL
Intervention: Mode of Feeding (breastfeeding versus bottle-feeding)
Description: Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
Study: NCT02175667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation
Description: Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
Study: NCT04755400

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline 9%
Description: 1 Liter of Isotonic saline administered I.V.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline 9%
Description: 1 Liter of Isotonic saline administered I.V.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate
Description: 24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium chloride
Description: 24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
Study: NCT04202757

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Study: NCT03302598

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serum C-reactive protein
Study: NCT01368354

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLTS
Description: CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
Study: NCT00748696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Extra®
Description: 260kcal and 20g protein per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: 3 sessions of resistance training per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined treatment
Description: 260kcal and 20g protein per day 3 sessions of resistance training per week
Study: NCT00276536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha-1b
Description: interferon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN
Description: IFN daily
Study: NCT03528486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Training I
Description: Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Training I
Description: Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
Study: NCT01954212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced complex oral health care
Description: Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~1. Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~2. Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~3. Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available.
Study: NCT04404725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects will be randomized to wear comfilcon A for one month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Subjects will be randomized to wear comfilcon A for one month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samfilcon A
Description: Subjects will be randomized to wear samfilcon A for one month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samfilcon A
Description: Subjects will be randomized to wear samfilcon A for one month.
Study: NCT00686764

Intervention type: OTHER
Intervention: Observational
Description: Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36).
Study: NCT01316237

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 50 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 100 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 300 mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 100 mg QD, Fasted

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 300 mg QD, Fasted

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 900 mg QD, Fasted

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620 tablet, 450 mg BID
Description: GS-6620 tablet, 450 mg BID

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620 tablet
Description: GS-6620 tablet, 900mg , BID

Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620 tablet
Description: GS-6620 tablet, 900 mg
Study: NCT00789776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo donor bone marrow transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV
Study: NCT01605305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
Study: NCT01438710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro
Description: LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
Study: NCT02735317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ulcer Gargle (FORRAD®)
Description: Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
Description: Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
Study: NCT04516616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)
Description: PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W